摘要
[目的]研究125I标记CEA人/鼠嵌合抗体rch24(125I鄄rch24)及淋巴瘤抗体IgG(125I鄄IgG)在荷人结肠癌裸鼠体内的分布,为放射免疫显像(RII)及临床应用提供依据。[方法]每鼠尾静脉注射抗体0.1ml(约100μCi),测定注射后24、48、96、168h肿瘤和血液、肝、肺等重要脏器的单位重量放射性比值(T/NT),各组织摄取百分比。[结果]125I鄄rch24注射后24～168h内,肿瘤部位出现选择性放射性浓聚;肿瘤组织在注射125I鄄rch24后,48h组织摄取百分比达到最大值28.06%;96h所有脏器T/NT比值均大于8.0;125I鄄IgG未出现放射性浓聚,呈全身分布。[结论]125I鄄rch24在荷人结肠癌裸鼠体内,可特异结合肿瘤组织,可望用于临床诊断和治疗。
To study the distribution of 125I labeled chimeric anti-carcinoembryonic antigen rch24 and lymphoma IgG in nude mice bearing human colon carcinoma xenografts and to provide the basis for radioimmunoimaging(RII) and clinical use. 0.1ml(100μCi) labeled antibody was injected into the tail of each mouse. Radioactivity ratio of tumor to non-tumor(T/NT) and percentage of injected dosage per gram tissue were measured after 24,48,96,168 hours injection respectively. Concentrated radioactivity was found in tumor tissue in 24～168 hours after 125I-rch24 injection. The peak value of percentage of injected dosage per gram tissue was 28.06% at 48 hours. All T/NT are more than 8.0 at 96 hours. Concentrated 125I-IgG was not found, 125I-IgG was distributed evenly in body. [Conclusion] 125I-rch24 can specifically localize in the tumor of nude mice bearing human colon carcinoma xenografts. It may be a potential radiopharmaceutical agent for the imaging and treatment for colon carcinoma.
出处
《肿瘤学杂志》
CAS
2004年第6期401-403,共3页
Journal of Chinese Oncology
基金
江苏省高校自然科学研究项目(02KJD320032)
